Clinical Trials

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

506 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03812549 2025-03-04

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

160 enrolled

Locally Advanced Non-Small Cell Lung Cancer

NCT05549037 2025-02-19

PACIFIC15

Phase 3 Recruiting

210 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05504278 2025-01-27

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Phase 1 Recruiting

144 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06747169 2024-12-27

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

32 enrolled

Squamous Non-Small Cell Lung Cancer SqNSCLC

NCT03872661 2024-12-06

NIBCUN

36 enrolled

Lung Neoplasms

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Phase NA Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05979818 2024-11-19

BRIO

Phase 1 Recruiting

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06688656 2024-11-14

Peri-E

Phase 2 Active not recruiting

Lung Neoplasms

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

45 enrolled

Lung Neoplasms

NCT06620822 2024-10-01

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

296 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04167657 2024-09-19

STAR

Phase 2 Completed

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06604351 2024-09-19

Example

39 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05244213 2024-07-08

NEOTIDE

35 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

90 enrolled

Resectable Non-small Cell Lung Cancer

NCT06479759 2024-06-28

ACCLAIM

50 enrolled

NSCLC

NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

20 enrolled

Phase 2 Active not recruiting

Advanced Non Small Cell Lung Cancer

NCT04326153 2024-02-01

Neo-Pre-IC

IIIA Stage Non-small Cell Lung Cancer

NCT06221462 2024-01-25

PRIORITY

Carcinoma, Non-Small-Cell Lung

NCT05088967 2024-01-16

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Phase 1 Terminated

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06198907 2024-01-10

JACKPOT33

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03802240 2023-11-27

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

492 enrolled

Non-Squamous Non-Small Cell Lung Cancer

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

21 enrolled

Lung Neoplasms

NCT04728724 2023-09-13

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05026593 2023-07-19

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

60 enrolled

SCLC

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

19 enrolled

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

42 enrolled

Advanced Lung Cancer

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

High-Risk Resectable NSCLC

NCT03150875 2023-02-28

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

290 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

357 enrolled 14 charts

Squamous NSCLC

NCT03607539 2023-02-27

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

397 enrolled 15 charts

Lung Neoplasms

NCT04177290 2023-02-27

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05118334 2023-02-23

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT05648071 2022-12-13

SPBPDC

Phase 3 Unknown

60 enrolled

Advanced Non-squamous Non-Small-Cell Lung Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Phase 1 Terminated

9 enrolled

SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT04459611 2022-07-12

neoSCORE

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04967625 2021-07-28

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

23 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04840758 2021-04-12

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Phase 1/2 Unknown

39 enrolled

Multiple Primary Lung Cancer

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04513301 2020-08-14

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

70 enrolled

Lung Neoplasms

NCT04486287 2020-07-24

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

44 enrolled